Which of the following tests measures the total quantity of prothrombin in the blood and monitors the…

Explanation

Core Concept: Prothrombin Time (PT) evaluates the extrinsic and common pathways of the coagulation cascade. It measures the time it takes for blood to clot and is the primary laboratory test used to monitor the efficacy and safety of vitamin K antagonist therapy (Warfarin). Results are standardized globally using the International Normalized Ratio (INR) to account for variations in laboratory reagents.

Clinical Presentation:

• Indicated for patients on warfarin therapy for conditions like atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism, or mechanical heart valves.
• Symptoms of abnormal clotting (supratherapeutic INR) include easy bruising, bleeding gums, hematuria, and melena.
• Complications include life-threatening intracranial or gastrointestinal hemorrhage if the INR is too high, or thromboembolic stroke if the INR is subtherapeutic.

Diagnosis:

• First-line diagnostic tool: PT/INR blood test to monitor anticoagulation levels.
• Gold standard diagnostic test: Serial PT/INR monitoring to maintain the target therapeutic range (typically 2.0-3.0) and pharmacogenomic testing (CYP2C9 and VKORC1 genotyping) in cases of extreme warfarin sensitivity or resistance.

Management:

• Acute management: Adjusting the warfarin dose based on the INR result. If severely supratherapeutic with active bleeding, administer Vitamin K, Prothrombin Complex Concentrate (PCC), or Fresh Frozen Plasma (FFP).
• Gold standard long-term/definitive management: Regular, lifelong monitoring of INR, maintaining dietary consistency regarding Vitamin K intake, or transitioning to Direct Oral Anticoagulants (DOACs) which do not require routine coagulation monitoring.